Sanofi's MS Drug Faces Setbacks, Delay in Approval

Sanofis experimental MS drug, tolebrutinib, faces setbacks; late-stage study for one form fails, US regulators delay decision for another. Despite high sales projections, Sanofi wont pursue approval for primary progressive MS. Confidence remains for non-relapsing secondary progressive MS, with FDA review extended and patients gaining access through special program.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.